Galvani Bioelectronics
Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.
Type | Subsidiary |
---|---|
Industry | Bioelectronics |
Founded | November 2016[1] |
Founders | [2] |
Headquarters | , |
Key people | Kristoffer Famm (President)[4] |
Parent | GlaxoSmithKline (55% equity interest)[3] |
Website | galvani |
History
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.
In November 2021, a team of laparoscopic surgeons successfully completed the first implantation of a Galvani device in a patient. [8]
References
- "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
- "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
- Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
- "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
- Kollewe, Julia (28 August 2017). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 3 August 2018.
- "Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future". Worldanalytics24.com. 23 January 2019. Retrieved 31 January 2019.
- "Galvani Bioelectronics". FierceBiotech. Retrieved 13 July 2020.
- "Verily Life Sciences". verily.com. Retrieved 15 February 2017.